Curated News
By: NewsRamp Editorial Staff
October 29, 2024
Tonix Pharmaceuticals CEO to Present at BIO-Europe Conference in Stockholm
Discuss on Reddit
LinkedIn
GithubTLDR
- Tonix Pharmaceuticals CEO to present at BIO-Europe® conference, showcasing strategic developments.
- Tonix Pharmaceuticals focuses on developing innovative therapies for pain management and infectious diseases.
- Tonix Pharmaceuticals aims to improve public health by advancing treatments for fibromyalgia and acute stress reactions.
- Tonix Pharmaceuticals awarded $34 million contract to develop antiviral agents targeting CD45 for military personnel readiness.
Impact - Why it Matters
This news highlights Tonix Pharmaceuticals' advancements in biopharmaceuticals and its strategic focus on pain management and public health solutions. Investors and stakeholders can gain insights into the company's developments and future directions by following the CEO's presentation at the BIO-Europe® conference.
Summary
Tonix Pharmaceuticals (NASDAQ: TNXP), a biopharmaceutical company, announced that CEO Seth Lederman, M.D., will present at the BIO-Europe® conference in Stockholm, Sweden. The presentation will focus on Tonix's developments and strategic direction.
Tonix is a biopharmaceutical company specializing in pain management and public health solutions. The company is set to submit an NDA for TNX-102 SL, a product candidate for fibromyalgia management, to the FDA this month. Additionally, Tonix was awarded a contract by the U.S. DoD to develop TNX-4200, small molecule antiviral agents targeting CD45.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Tonix Pharmaceuticals CEO to Present at BIO-Europe Conference in Stockholm
